This new study shines a spotlight on the complex, sex-specific differences in Long COVID (LC)—particularly for those who meet diagnostic criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The findings hold important implications for understanding patient susceptibility, disease progression, and future therapies, especially for women who appear to suffer more severe symptoms linked to persistent inflammation and neuroendocrine disruption.
Persistent Symptoms and Patient Demographics
Long COVID continues to be a major global health challenge, with sufferers experiencing persistent, disabling symptoms across multiple organ systems, sometimes years after initial SARS-CoV-2 infection. Many LC patients present with extreme fatigue and cognitive difficulties, overlapping with ME/CFS symptoms. In this study’s cohort, almost 70% of LC patients were women—a pattern echoed by other large studies—and women had significantly greater symptom burden and intensity compared to men.
Sex-Specific Immune Response and Inflammation
One of the key study findings is the discovery of a distinct immune profile in female LC patients (LCF) with ME/CFS. These women showed a marked shift toward myelopoiesis (production of immune cells such as neutrophils and monocytes), and—critically—a reduction in lymphocytes and regulatory T cells, hallmarks of a persistently activated immune system. Increased neutrophils and monocytes in LCF suggest heightened inflammation and reduced immune regulation, which often translates to prolonged tissue damage and poorer recovery outcomes.
Further, elevated levels of CD71+ erythroid cells and impaired erythropoiesis were seen in LCF patients, potentially contributing to both fatigue and organ stress. This abnormal process is linked to the secretion of artemin, shown to exacerbate pain and cognitive symptoms, and may also help explain the unique neuroinflammatory patterns revealed in transcriptomic analyses.
Hormonal Dysregulation and Gut Barrier Dysfunction
The study uncovered significant differences in sex hormone profiles between LC subgroups. Females demonstrated lower testosterone levels, while males had reduced estradiol. Both exhibited decreased cortisol—a stress response hormone. These imbalances may play a dual role: exacerbating immune dysfunction, and prolonging recovery via effects on tissue repair. In parallel, LCF patients showed biomarkers of gut barrier dysfunction and a more pro-inflammatory cytokine signature, adding another layer of complexity to their symptoms and risk profiles.
Neuroinflammation and Cognitive Impairments
Transcriptomic analysis highlighted neuroinflammatory signatures in LCF, providing a molecular basis for often-reported cognitive symptoms such as brain fog and impaired memory. Biomarker profiling now enables differentiation between LCF and male LC (LCM) patients, and may help clinicians predict sex-specific disease courses and outcomes.
Clinical Implications and Therapy Development
Current evidence suggests LC with ME/CFS is characterized by profound, sex-specific immune and hormonal changes, with women disproportionately affected by chronic, low-grade inflammation and immune dysregulation. These insights underline the importance of developing sex-tailored clinical interventions—including hormone replacement strategies, and personalized immune modulation therapies to better address the unique needs of female long COVID patients.
In sum, this study not only clarifies why women are at greater risk for prolonged LC but also identifies molecular pathways and potential therapeutic targets to advance individualized care—an urgent need as the burden of long COVID continues to grow. Researchers suggest that future treatments should be informed by sex-linked immunological and hormonal differences for optimal efficacy and recovery
